Trial Profile
A Randomised, Open-labelled, Single Dose, Dose-escalation Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pegylated Long-acting Human Growth Hormone (NNC126-0083) Compared to Norditropin NordiFlex® in Growth Hormone Deficient Children
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 17 Apr 2021 Pooled modelling analysis of data from ClinicalTrials.gov identifiers NCT01973244, NCT00936403 and NCT01706783 published in the Clinical Pharmacokinetics
- 03 Apr 2014 New source identified and integrated (European Clinical Trials Database; EudraCT2008-008240-25)
- 28 Mar 2014 New trial record